Brought to you by 
Aquinox and Neoleukin merge to develop immunotherapies
14 Sep 2020
Executive Summary
Public Vancouver-based biotech Aquinox Pharmaceuticals Inc. acquired Neoleukin Therapeutics Inc. (de novo protein design technology for cancer drug development) in a reverse merger through which Aquinox will assume the Neoleukin name and Neoleukin’s executive staff.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aquinox and Neoleukin merge to develop immunotherapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice